Nanoparticle-based delivery systems could optimize SH003 dosing and tumor targeting, while combinatorial approaches with CAR-T cells, PD-1/PD-L1 blockade, or STING agonists may potentiate cytotoxic T-cell activity and overcome microenvironmental resistance. This evidence concerns the gene STING1 and neoplasm.